Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
Department of Radiology, Division of Neuroradiology, Mayo Clinic, Jacksonville, Florida, USA.
Epileptic Disord. 2024 Oct;26(5):626-637. doi: 10.1002/epd2.20255. Epub 2024 Jul 30.
Neuromodulation is a viable option for patients with drug-resistant epilepsies. We reviewed the management of patients with two deep brain neurostimulators. In addition, patients implanted with a device targeting the centromedian-parafascicular (CM-Pf) nuclear complex supplements this report to provide an illustrative case to implantation and programming a patient with three active devices.
A narrative review using PubMed and Embase identified patients with drug-resistant epilepsy implanted with more than one neurostimulator was performed. Combinations of vagus nerve stimulation (VNS), deep brain stimulation (DBS), and responsive neurostimulation (RNS) were identified. We provide a background of a newly reported case of an adult with a triple implant eventually responding to CM-Pf DBS as the third implant following suboptimal benefit from VNS and RNS.
In review of the literature, dual-device therapy is increasing in reports of use with combinations of VNS, RNS, and DBS to treat patients with drug-resistant epilepsy. We review dual-device implants with thalamic DBS device combinations, functional neural networks, and programming patients with dual devices. CM-Pf is a new target for DBS and has shown a variable response in focal epilepsy. We report the unique case of 28-year-old male with drug-resistant focal epilepsy who experienced a 75% seizure reduction with CM-Pf DBS as his third device after suboptimal responses to VNS and RNS. After 9 months, he also experienced seizure freedom from recurrent focal to bilateral tonic-clonic seizures. No medical or surgical complications or safety issues were encountered.
We demonstrate safety and feasibility in an adult combining active VNS, RNS, and CM-Pf DBS. Patients with dual-device therapy who experience a suboptimal response to initial device use at optimized settings should not be considered a neuromodulation "failure." Strategies to combine devices require a working knowledge of brain networks.
神经调节是耐药性癫痫患者的可行选择。我们回顾了两名接受深部脑神经刺激器治疗的患者的管理情况。此外,植入靶向中央中缝核-旁正中核(CM-Pf)核复合体设备的患者补充了本报告,提供了一个具有三个活动设备的患者植入和编程的说明性案例。
使用 PubMed 和 Embase 进行叙述性综述,确定了植入多个神经刺激器的耐药性癫痫患者。确定了迷走神经刺激(VNS)、深部脑刺激(DBS)和反应性神经刺激(RNS)的组合。我们提供了一个新报告病例的背景,该病例是一名成年患者,在 VNS 和 RNS 效果不佳后,CM-Pf DBS 作为第三个植入物,最终对其产生反应。
在文献综述中,双设备疗法在报告中越来越多地使用 VNS、RNS 和 DBS 的组合来治疗耐药性癫痫患者。我们回顾了具有丘脑 DBS 设备组合、功能神经网络和双设备编程的双设备植入物。CM-Pf 是 DBS 的新靶点,在局灶性癫痫中表现出不同的反应。我们报告了一名 28 岁男性的独特病例,他患有耐药性局灶性癫痫,在 VNS 和 RNS 效果不佳后,CM-Pf DBS 作为他的第三个设备,使他的癫痫发作减少了 75%。9 个月后,他还经历了从复发性局灶性到双侧强直阵挛性发作的无发作。没有遇到任何医疗或手术并发症或安全问题。
我们在一名成人中证明了 VNS、RNS 和 CM-Pf DBS 联合使用的安全性和可行性。在优化设置下对初始设备使用反应不佳的双设备治疗患者不应被视为神经调节“失败”。结合设备的策略需要对大脑网络有深入的了解。